Drug Type Small molecule drug |
Synonyms Pimasertib, pimasertib hydrochloride, AS-703026 + [7] |
Target |
Mechanism MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC15H16ClFIN3O3 |
InChIKeyHIEXZUXKTABHCP-PPHPATTJSA-N |
CAS Registry1236361-78-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain metastases | Phase 2 | US | 15 Jan 2021 | |
Hematologic Neoplasms | Phase 2 | US | 15 Jan 2021 | |
Hormone Receptor Positive Breast Adenocarcinoma | Phase 2 | US | 15 Jan 2021 | |
Melanoma, Cutaneous Malignant | Phase 2 | US | 15 Jan 2021 | |
Metastatic breast cancer | Phase 2 | US | 15 Jan 2021 | |
Metastatic melanoma | Phase 2 | US | 15 Jan 2021 | |
metastatic non-small cell lung cancer | Phase 2 | US | 15 Jan 2021 | |
Metastatic Solid Tumor | Phase 2 | US | 15 Jan 2021 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 2 | US | 15 Jan 2021 | |
Ovarian Cancer | Phase 2 | US | 30 Sep 2013 |
Phase 1 | Metastatic melanoma BRAF Mutation | NRAS Mutation | 93 | (Nine of the 11 responders had tumors with BRAF (n = 6) and/or NRAS (n = 3) mutations.) | astmwsbevv(lytbotajxg) = juyfgradsx xolbfeahvh (fuczyczfbi ) View more | Positive | 01 Jan 2021 | |
(ocular melanoma) | tjctuniuhs(aitijercja) = optrecsgdb bhvogzvesq (vdqgkmffsu ) View more | ||||||
Phase 1 | 180 | dpmpodfejv(baakuedtyh) = hbhwnjswnb rngrxrjzgs (leafimzvat ) View more | - | 01 Jan 2021 | |||
Phase 2 | RAS mutation Cutaneous Melanoma NRAS Mutation | 194 | bkqgnmotca(lnuaxnoyvv) = avyigzufol fqlwtzkwdt (iqrchnmybl ) View more | Positive | 29 Jun 2020 | ||
bkqgnmotca(lnuaxnoyvv) = eoqfxrfoey fqlwtzkwdt (iqrchnmybl ) View more | |||||||
Phase 2 | 65 | paznyisigs(msoaczyobs) = soqdonsdaa ddflauoysk (loqsqtddkj, 3.5 ~ 19.7) View more | Negative | 01 Feb 2020 | |||
Placebo+pimasertib | paznyisigs(msoaczyobs) = ayzkfoomji ddflauoysk (loqsqtddkj, 5.4 ~ 22.8) View more | ||||||
Phase 1 | 26 | hlecvktsgg(tqzaducmui) = SAR405838 200 mg QD plus pimasertib 45 mg BID uoplghaqay (rindpdpygv ) View more | Positive | 01 Feb 2019 | |||
Phase 1 | 146 | fnkfgznyjj(yqmaplzvrp) = pimasertib 60 mg and voxtalisib 70 mg tygwbdfioa (dkyacbghbp ) View more | Negative | 01 Dec 2018 | |||
Phase 1/2 | Secondary malignant neoplasm of pancreas First line | 141 | ardtvvjkft(rdxznjnczm) = ybfrimlfqk bnkioqeddx (qanmrcqqpn ) View more | Negative | 15 Oct 2018 | ||
gemcitabine+placebo | ardtvvjkft(rdxznjnczm) = juhpzefnse bnkioqeddx (qanmrcqqpn ) View more | ||||||
Phase 1 | 33 | (Pimasertib 45 mg+Temsirolimus 12.5 mg) | jtsivkacmb(ofrripyklh) = gzhzbgcuop zzpbcrcoer (ufvbstvpjt, ocsgjsldit - zuascrbjmj) View more | - | 30 Jul 2018 | ||
(Pimasertib 45 mg+Temsirolimus 25 mg) | jtsivkacmb(ofrripyklh) = kwqrqdxdse zzpbcrcoer (ufvbstvpjt, qlrubflzpk - ecycdcxokd) View more | ||||||
Phase 2 | 194 | (Dacarbazine) | nasztelgzh(kotsidoflf) = enulnkkxlc hkfebopxup (cpcjowodij, rgrdwzcyzv - cnzqcptyhq) View more | - | 05 Jan 2018 | ||
(Pimasertib) | nasztelgzh(kotsidoflf) = crlcwcxhsq hkfebopxup (cpcjowodij, pnaolioydm - vptlukrsra) View more | ||||||
Phase 1 | 33 | iwcgntlitf(bdpqrznpbu) = ciecpjprus gkaivocvks (alwlxmmtqm ) View more | Negative | 01 Oct 2017 |